Kaufman PA Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
Reviewed by Ulas D. Bayraktar, MD on Dec 12, 2016
jghghjghjghhgj
